Q3 2024 TELA Bio Inc Earnings Call Transcript
Key Points
- TELA Bio Inc (TELA) reported a strong third quarter with a 26% year-over-year revenue increase, reaching $19 million.
- The company experienced significant growth in its European business, with a 67% increase from the prior year period.
- TELA Bio Inc (TELA) successfully closed a public offering, adding $43 million in cash to its balance sheet, enhancing its financial position.
- The company achieved its first million-dollar month in Europe, indicating strong international market penetration.
- TELA Bio Inc (TELA) implemented strategic initiatives that resulted in a more productive sales organization, contributing to sustainable growth.
- Gross margin decreased slightly to 68% from 69% in the prior year period due to higher charges for excess and obsolete inventory.
- Sales and marketing expenses increased to $16.5 million, primarily due to higher compensation, severance costs, and additional consulting and travel expenses.
- The company reported a net loss of $10.4 million for the third quarter, although this was an improvement from the $11 million loss in the same period in 2023.
- There is potential for ASP (Average Selling Price) pressure due to the mix shift towards IHR products, which could impact overall revenue.
- The company is still monitoring potential impacts from IV fluid shortages due to recent natural disasters, which could affect elective procedure volumes.
Good afternoon, ladies and gentlemen and welcome to the Tela Bio third quarter, 2024. (Operators Instruction).
I would now like to turn the conference over to Louisa Smith from the Gilmartin Group. Please go ahead.
Thank you, Leonardo and good afternoon, everyone earlier today, Tela Bio released financial results for the third quarter of 2024. A copy of the press release is available on the company's website. Joining me on today's call are Tony Koblish, President and Chief Executive Officer and Roberto Cuca, Chief Operating Officer and Chief Financial Officer.
Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the sec including without limitation, the company's annual report on form 10-K and quarterly reports on forms 10-Q which identify the specific factors that may cause actual results or events to differ materially from those described in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
